Cervical cancer: Are there potential new targets? an update on preclinical and clinical results

Federica Tomao, Chiara Di Tucci, Ludovica Imperiale, Serena Maria Boccia, Claudia Marchetti, Innocenza Palaia, Ludovico Muzii, Pierluigi Benedetti Panici

Research output: Contribution to journalArticle

Abstract

According to international guidelines, treatment of cervical cancer (CC) consists of surgery in early stages and of chemoradiation in locally advanced disease. Metastatic disease is usually treated with palliative chemotherapeutic regimens, but cytostatic drugs present significant side effects and show limited activity. Thus, the discovery of new anticancer agents, interfering with molecular targets expressed by the tumor’s microenvironment or by the tumor cell itself, represents a possible chance for the struggle against this tumor. The aim of this review is to report all targets that have been investigated in preclinical and clinical studies. We discuss these potential targets according to “targeted therapies” NCI classification. The most investigated molecular targets have been epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF), both involved in CC etiopathogenesis. Studies with anti-angiogenetic agents showed encouraging clinical efficacy and acceptable toxicity. Other interesting results have been obtained by immunotherapeutic strategies. Since biological characteristics of CC, especially in recurrent disease, are still partially unknown, future studies are necessary to understand mechanisms involved in CC carcinogenesis, in order to give to patients the most tailored and efficient treatments.

Original languageEnglish
Pages (from-to)1107-1120
Number of pages14
JournalCurrent Drug Targets
Volume15
Issue number12
Publication statusPublished - Jan 1 2014

Fingerprint

Uterine Cervical Neoplasms
Tumors
Angiogenesis Inhibitors
Cytostatic Agents
Epidermal Growth Factor Receptor
Antineoplastic Agents
Surgery
Vascular Endothelial Growth Factor A
Tumor Microenvironment
Toxicity
Cells
Neoplasms
Carcinogenesis
Therapeutics
Guidelines

Keywords

  • Cervical cancer
  • Molecular pathways
  • Preclinical studies
  • Targeted therapies

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine
  • Medicine(all)

Cite this

Tomao, F., Di Tucci, C., Imperiale, L., Boccia, S. M., Marchetti, C., Palaia, I., ... Panici, P. B. (2014). Cervical cancer: Are there potential new targets? an update on preclinical and clinical results. Current Drug Targets, 15(12), 1107-1120.

Cervical cancer : Are there potential new targets? an update on preclinical and clinical results. / Tomao, Federica; Di Tucci, Chiara; Imperiale, Ludovica; Boccia, Serena Maria; Marchetti, Claudia; Palaia, Innocenza; Muzii, Ludovico; Panici, Pierluigi Benedetti.

In: Current Drug Targets, Vol. 15, No. 12, 01.01.2014, p. 1107-1120.

Research output: Contribution to journalArticle

Tomao, F, Di Tucci, C, Imperiale, L, Boccia, SM, Marchetti, C, Palaia, I, Muzii, L & Panici, PB 2014, 'Cervical cancer: Are there potential new targets? an update on preclinical and clinical results', Current Drug Targets, vol. 15, no. 12, pp. 1107-1120.
Tomao F, Di Tucci C, Imperiale L, Boccia SM, Marchetti C, Palaia I et al. Cervical cancer: Are there potential new targets? an update on preclinical and clinical results. Current Drug Targets. 2014 Jan 1;15(12):1107-1120.
Tomao, Federica ; Di Tucci, Chiara ; Imperiale, Ludovica ; Boccia, Serena Maria ; Marchetti, Claudia ; Palaia, Innocenza ; Muzii, Ludovico ; Panici, Pierluigi Benedetti. / Cervical cancer : Are there potential new targets? an update on preclinical and clinical results. In: Current Drug Targets. 2014 ; Vol. 15, No. 12. pp. 1107-1120.
@article{7e2b5c1d88ec41abb6242a7c6977f47d,
title = "Cervical cancer: Are there potential new targets? an update on preclinical and clinical results",
abstract = "According to international guidelines, treatment of cervical cancer (CC) consists of surgery in early stages and of chemoradiation in locally advanced disease. Metastatic disease is usually treated with palliative chemotherapeutic regimens, but cytostatic drugs present significant side effects and show limited activity. Thus, the discovery of new anticancer agents, interfering with molecular targets expressed by the tumor’s microenvironment or by the tumor cell itself, represents a possible chance for the struggle against this tumor. The aim of this review is to report all targets that have been investigated in preclinical and clinical studies. We discuss these potential targets according to “targeted therapies” NCI classification. The most investigated molecular targets have been epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF), both involved in CC etiopathogenesis. Studies with anti-angiogenetic agents showed encouraging clinical efficacy and acceptable toxicity. Other interesting results have been obtained by immunotherapeutic strategies. Since biological characteristics of CC, especially in recurrent disease, are still partially unknown, future studies are necessary to understand mechanisms involved in CC carcinogenesis, in order to give to patients the most tailored and efficient treatments.",
keywords = "Cervical cancer, Molecular pathways, Preclinical studies, Targeted therapies",
author = "Federica Tomao and {Di Tucci}, Chiara and Ludovica Imperiale and Boccia, {Serena Maria} and Claudia Marchetti and Innocenza Palaia and Ludovico Muzii and Panici, {Pierluigi Benedetti}",
year = "2014",
month = "1",
day = "1",
language = "English",
volume = "15",
pages = "1107--1120",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "12",

}

TY - JOUR

T1 - Cervical cancer

T2 - Are there potential new targets? an update on preclinical and clinical results

AU - Tomao, Federica

AU - Di Tucci, Chiara

AU - Imperiale, Ludovica

AU - Boccia, Serena Maria

AU - Marchetti, Claudia

AU - Palaia, Innocenza

AU - Muzii, Ludovico

AU - Panici, Pierluigi Benedetti

PY - 2014/1/1

Y1 - 2014/1/1

N2 - According to international guidelines, treatment of cervical cancer (CC) consists of surgery in early stages and of chemoradiation in locally advanced disease. Metastatic disease is usually treated with palliative chemotherapeutic regimens, but cytostatic drugs present significant side effects and show limited activity. Thus, the discovery of new anticancer agents, interfering with molecular targets expressed by the tumor’s microenvironment or by the tumor cell itself, represents a possible chance for the struggle against this tumor. The aim of this review is to report all targets that have been investigated in preclinical and clinical studies. We discuss these potential targets according to “targeted therapies” NCI classification. The most investigated molecular targets have been epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF), both involved in CC etiopathogenesis. Studies with anti-angiogenetic agents showed encouraging clinical efficacy and acceptable toxicity. Other interesting results have been obtained by immunotherapeutic strategies. Since biological characteristics of CC, especially in recurrent disease, are still partially unknown, future studies are necessary to understand mechanisms involved in CC carcinogenesis, in order to give to patients the most tailored and efficient treatments.

AB - According to international guidelines, treatment of cervical cancer (CC) consists of surgery in early stages and of chemoradiation in locally advanced disease. Metastatic disease is usually treated with palliative chemotherapeutic regimens, but cytostatic drugs present significant side effects and show limited activity. Thus, the discovery of new anticancer agents, interfering with molecular targets expressed by the tumor’s microenvironment or by the tumor cell itself, represents a possible chance for the struggle against this tumor. The aim of this review is to report all targets that have been investigated in preclinical and clinical studies. We discuss these potential targets according to “targeted therapies” NCI classification. The most investigated molecular targets have been epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF), both involved in CC etiopathogenesis. Studies with anti-angiogenetic agents showed encouraging clinical efficacy and acceptable toxicity. Other interesting results have been obtained by immunotherapeutic strategies. Since biological characteristics of CC, especially in recurrent disease, are still partially unknown, future studies are necessary to understand mechanisms involved in CC carcinogenesis, in order to give to patients the most tailored and efficient treatments.

KW - Cervical cancer

KW - Molecular pathways

KW - Preclinical studies

KW - Targeted therapies

UR - http://www.scopus.com/inward/record.url?scp=84926283854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926283854&partnerID=8YFLogxK

M3 - Article

C2 - 25300780

AN - SCOPUS:84926283854

VL - 15

SP - 1107

EP - 1120

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 12

ER -